Circular RNAs (circRNAs) regulate gene expression by acting as a 'sponge' for microRNAs (miRs) and play crucial roles in tumorigenesis, including in bladder cancer (BC). circRNA-baculoviral IAP repeat-containing 6 (circ-BIRC6) has been reported to participate in the pathogenesis of several cancer types. The present study aimed to elucidate the roles and potential mechanisms of circ-BIRC6 in the progression of BC. circ-BIRC6 expression levels in BC cell lines were determined using reverse transcription-quantitative PCR. Following circ-BIRC6 knockdown, cell proliferation, invasion and migration were detected using Cell Counting Kit-8, colony formation, Transwell and wound healing assays, respectively. Western blotting was also conducted to evaluate the expression levels of X-box binding protein 1 (XBP1) and epithelial-mesenchymal transition (EMT)-associated proteins. In addition, rescue experiments were performed using by transfecting a miR-495-3p inhibitor into T24 cells following circ-BIRC6 knockdown.

The interactions between circ-BIRC6, miR-495-3p and XBP1 was verified using dual luciferase reporter assays. Moreover, T24 cells with circ-BIRC6 knockdown and miR-495-3p inhibitor transfection were used for the tumor-bearing experiment. Tumor growth was observed and Ki-67 expression was determined using immunohistochemistry. The results demonstrated that circ-BIRC6 expression was upregulated in BC cell lines. Moreover, circ-BIRC6 knockdown notably attenuated the proliferation, invasion, migration and EMT of BC cells, which was blocked by the miR-495-3p inhibitor. It was also identified that circ-BIRC6 sponged miR-495-3p to regulate XBP1 expression. In addition, results from the xenograft experiments indicated that the knockdown of circ-BIRC6 and miR-495-3p expression significantly inhibited tumor growth. It was also found that the expression levels of XBP1, Ki-67 and EMT-associated proteins in tumor tissues of the co-transfection group were markedly restored compared with the circ-BIRC6 knockdown group. In conclusion, these findings demonstrated that circ-BIRC6 knockdown suppressed BC tumorigenesis and progression via regulation of the miR-495-3p/XBP1 signaling axis, offering a promising therapeutic target for the treatment of BC.

Introduction

Bladder cancer (BC) is one of the most common malignancies in the genitourinary tract and has high morbidity and mortality rates (1). According to the statistics, >400,000 new cases of BC are diagnosed annually and ≥2 million patients currently suffer from this disease (2,3). Despite therapeutic interventions, such as surgery, chemotherapy and radiotherapy, the 5-year survival rate of BC remains low, which is a significant economic burden (4-6). Thus, it is of great importance to identify novel biomarkers of BC and investigate the genetic regulatory networks involved in BC progression to improve patient prognosis and clinical outcomes.

Circular RNA (circRNA), a newly identified member of the non-coding RNA family, is characterized by a covalently closed loop without a 5’cap and 3’polyadenylated tail (7). Accumulating evidence has revealed that circRNAs exert key effects on multiple biological and pathological processes, such as proliferation, apoptosis, migration and metastasis, indicating that they may be involved in the occurrence and development of numerous types of disease, including cancer (8-10). circRNAs serve as competitive endogenous RNAs to modulate the activity of microRNAs (miRNAs/miRs) and restore miRNA-mediated suppression of target genes (11,12). circRNA-baculoviral IAP repeat-containing 6 (circ-BIRC6) is generated by the back-splicing of the BIRC6 transcript (NM_016252) and has been reported to be associated with oncogenesis (13,14). Previous studies have reported that BIRC6 expression was significantly upregulated in several human cancer types, such as hepatocellular carcinoma, prostate cancer and lung cancer (15-17). However, to the best of our knowledge, the role of circ-BIRC6 in BC remains to be elucidated and is therefore worthy of further investigations.

Correspondence to: Dr Bin Liu, Department of Urology, The Third Xiangya Hospital, Central South University, 138 Tongzipo Road, Yuelu, Changsha, Hunan 410013, P.R. China
E-mail: liubing32346@163.com

Key words: bladder cancer, circular RNA baculoviral IAP repeat-containing 6, epithelial-mesenchymal transition
The present study analyzed the expression levels of circ-BIRC6 in BC cell lines. Then, the effects of circ-BIRC6 on the biological functions of BC cells and on tumor growth were explored in vitro and in vivo. The potential underlying mechanisms of the effects of circ-BIRC6 in BC were also investigated. These results may offer novel insight into potential biomarkers for diagnosing and predicting the prognosis of patients with BC.

Materials and methods

Cell lines and culture. Several BC cell lines (SW780, T24, J82 and 5637) and a human immortalized uroepithelium cell line (SV-HUC-1) were purchased from the American Type Culture Collection. SV-HUC-1, SW780 and T24 cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.), while J82 and 5637 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.). All media were supplemented with 10% FBS (Gibco; Thermo Fisher Scientific, Inc.). Cells were maintained in an incubator with 5% CO₂ at 37°C.

Cell transfection. The pLVX lentiviral short hairpin RNA (shRNA/sh) circ-BIRC6 (sh-circ-BIRC6#1 and sh-circ-BIRC6#2) and sh-negative control (NC) vectors were synthesized by Shanghai GeneChem Co., Ltd. The miR-495-3p mimic (5'-AAACAAAACATGGTGCACCTCTT T-3'; 50 nM), miR-495-3p inhibitor (5'-GCTTTTATATGTG ACGAAAACAA-3'; 50 nM) and their controls [mimic NC (5'-ATCGTGTAGTCGTAGCTAGCT-3'; 50 nM) and NC inhibitor (5'-CGATCGCGTGCGTACCT-3'; 50 nM)] were obtained from Shanghai GenePharma Co., Ltd. T24 cells (2x10⁵ cells per well) were plated and incubated in 6-well plates for 24 h. The transfection procedure was conducted at 37°C using Lipofectamine® 2000 reagent (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The transfection efficiency was evaluated using reverse transcription-quantitative PCR (RT-qPCR) following 48 h of transfection. The transfected cells were used for subsequent experiments at 48 h after transfection.

Cell proliferation assay. Briefly, 5x10⁴ T24 cells/well were plated into 96-well culture plates and cultured at 37°C. Following 24, 48 or 72 h of incubation, 10 µl Cell Counting Kit-8 (CCK-8) reagent (Shanghai Yeasen Biotechnology Co., Ltd.) was added into each well and the plates were cultured for a further 4 h at 37°C. At 0 h, T24 cells would have just been seeded into a 96-well plate and would not reflect the activity of adherent cells. Therefore, the 0 h time point was omitted from the measurements. The optical density of each sample was determined at a wavelength of 450 nm using a microplate reader.

Colonies formation assay. Following transfection, T24 cells were plated into 6-well plates (500 cells/well). After incubation at 37°C for 7-10 days, the cell colonies were washed with PBS, fixed with 4% paraformaldehyde for 10 min at room temperature and stained with 0.1% crystal violet for 15 min at room temperature. Images of the colonies were captured using a light microscope (Olympus Corporation; magnification, x10).

Transwell assay. The invasive ability of T24 cells was determined using Transwell plates with 8-µm pore inserts; the membranes were precoated with Matrigel (BD Biosciences) at 37°C for 6 h. A total of 2x10⁵ cells/well were resuspended in 200 µl serum-free DMEM (Invitrogen; Thermo Fisher Scientific, Inc.) and plated into the upper chambers of the Transwell plates. The lower chambers were filled with 600 µl DMEM supplemented with 10% FBS. After incubation for 24 h at 37°C, the invasive cells were fixed with 4% paraformaldehyde 20 min at 37°C and stained with 0.1% crystal violet 10 min at 37°C for subsequent imaging and counting. Stained cells were visualized using an inverted light microscope (Olympus Corporation; magnification, x100).

Wound healing assay. For the wound healing assay, T24 cells were plated into 6-well plates (5x10⁴ cells/well) and cultured until they reached 90% confluence. Then, cells were incubated overnight in serum-free DMEM prior to initiating the experiment. The cell monolayer was subsequently scratched with a sterilized 100-µl pipette tip. Following 24 h of incubation at 37°C, the migration of cells was visualized using an inverted light microscope (Olympus Corporation; magnification, x100). Semi-quantitative analysis of the wound healing area was performed using ImageJ software (version 1.52r; National Institutes of Health).

Dual luciferase reporter assay. To study the mechanism via which circ-BIRC6 promotes BC progression, the potential miRNAs binding to circ-BIRC6 were predicted using the StarBase database (starbase.sysu.edu.cn). The wild-type (WT) and mutant (MUT) binding sites of miR-495-3p in the circ-BIRC6 or X-box binding protein 1 (XBP1) 3'-untranslated region (UTR) were sub-cloned into a pmirGLO dual luciferase reporter vector (Promega Corporation) to construct circ-BIRC6 WT/MUT and XBP1-WT/MUT vectors. Briefly, 5x10⁴ T24 cells were seeded into 24-well plates and cultured for 24 h at 37°C. The plasmids were then co-transfected with miR-495-3p mimic or mimic NC into T24 cells using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The transfection efficiency was evaluated using reverse transcription-quantitative PCR (RT-qPCR) following 48 h of transfection. The transfected cells were used for subsequent experiments at 48 h after transfection.

Immunofluorescence assay. Transfected cells were fixed with 4% paraformaldehyde at room temperature for 20 min, followed by the addition of 0.05% Triton X-100 solution at room temperature for 10 min. After blocking with 3% BSA (Sigma-Aldrich; Merck KGaA) at 37°C for 90 min, cells were incubated with a primary antibody against Ki-67 (cat. no. 11882S; 1:1,000; Cell Signaling Technology, Inc.) at 4°C overnight, followed by probing with the DyLight™ 488-conjugated secondary antibody (cat. no. ab96899; 1:250; Abcam) at 37°C for 1.5 h in the dark. The nuclei were stained with DAPI (Roche Diagnostics) in the dark for 5 min at room temperature. Images were captured under a fluorescence microscope (Olympus Corporation; magnification, x200) and the relative fluorescence intensity was used to quantify the Ki-67-positive cells in three randomly selected fields of view. The relative fluorescence intensity was normalized to the average optical density of the control group.
**In vivo xenograft experiments.** A total of 12 BALB/c nude mice (age, 5-6 weeks; weight, ~18-22 g) were provided by the Shanghai Slac Animal Laboratory, and the animal experiments were approved by the Animal Care and Use Committee of The Third Xiangya Hospital, Central South University (Changsha, China). Mice were housed under pathogen-free conditions with a 12-h light/dark cycle, constant temperature of 25-27°C and constant humidity of 45-50%. Mice had free access to food and water. Animals were randomly allocated into four groups (3 mice/group): sh-NC, sh-circ-BIRC6#1, sh-circ-BIRC6#1+NC inhibitor and sh-circ-BIRC6#1+miR-495-3p inhibitor groups. T24 cells transfected with lentiviral sh-circ-BIRC6#1, miR-495-3p or both were subcutaneously injected into the flank of nude mice (5x10^6 cells/mouse). Each mouse (7 weeks) was injected with 30 µl cell suspension. Subsequently, the mice were maintained for 3 weeks. Tumor volume was recorded every 3 days. Tumor volume was calculated using the formula: Length x width^2/2. At the end of the experiments, all animals were sacrificed with an intraperitoneal injection of 100 mg/kg sodium pentobarbital (body weight). The tumor tissues were obtained for further investigation. The maximum tumor diameter and volume observed in the study were 19 mm and 1,519 mm^3, respectively.

**Immunohistochemistry analysis.** Tumor tissues were fixed in 10% buffered formalin 24 h at room temperature and then embedded in paraffin. Paraffin-embedded tissue sections (4 µm thick) were deparaffinized with xylene and then rehydrated with a graded descending series of ethanol (100, 95 and 80%). Following antigen retrieval in boiling water with a 10 mM citrate buffer, endogenous hydrogen peroxidase activity was blocked by incubation with 10% hydrogen peroxide for 30 min at room temperature. The tissue samples were incubated with a primary rabbit anti-Ki-67 antibody (cat. no. 9027T; 1:500; Cell Signaling Technology, Inc.) at 4°C overnight, then with an HRP-conjugated anti-rabbit IgG secondary antibody (cat. no. ab181658; 1:1,000; Abcam) for 2 h at room temperature. Subsequently, the tissue sections were treated with 3,3'-diaminobenzidine solution at room temperature for 3-5 min and counterstained with hematoxylin at room temperature for 5 min. Sections were viewed under an inverted light microscope (Olympus Corporation; magnification, x100).

**RT-qPCR.** Total RNA was extracted from cells or tumor tissues using TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Total RNA was reverse transcribed into cDNA using HiScript II (Vazyme Biotech Co., Ltd.) according to the manufacturer's protocol. qPCR to determine circ-BIRC6, miR-495-3p and XBPI expression levels was subsequently performed using SYBR Select Master mix (Tiangen Biotech Co., Ltd.) on an ABI 7300 Real-Time PCR detection system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used: Initial denaturation at 95°C for 10 min; followed by 40 cycles of denaturation at 95°C for 15 sec and annealing at 60°C for 1 min; and a final extension of 10 min at 72°C. The primers used were: circ-BIRC6 forward, 5'-TGA AAGGTTCTTGACGACAT-3' and reverse, 5'-GCTGGGG GTTCGTTCAACAATC-3'; miR-495-3p forward, 5'-AAACAA ACAUGUGUGCAUUU-3' and reverse, 5'-GAAGUGCAUUU-3'; XBPI forward, 5'-ATGGATGCCC CTGTTTGTGTAAGAAGGA-3' and reverse, 5'-TCGACTGCT GTGCACTCA-3'; XBPI-3p forward, 5'-GCCACTCACTACG TGACCTCT-3' and reverse, 5'-CCAGAATGCCCCAACA GATATCAG-3'; U6 forward, 5'-CTCGCTTGGCGACGA CA-3' and reverse, 5'-AAGCCCTACGAAATTTGCGT-3'; GAPDH forward, 5'-ACAACCTTGGATCTGTAAGG-3' and reverse, 5'-GCCATACGCCACAGGTTC-3'; U6 levels were used to normalize miR-495-3p expression. GAPDH was the endogenous control for circ-BIRC6. The relative expression levels were quantitatively analyzed using the 2^−ΔΔCt method (18).

**Western blotting.** Total protein was extracted from cells or tumor tissues using RIPA lysis buffer (Beyotime Institute of Biotechnology). Protein concentration was quantified using a BCA assay kit (Beyotime Institute of Biotechnology) and equal amounts of protein (40 µg protein/lane) were separated via 10% SDS-PAGE. The proteins were subsequently transferred onto PVDF membranes (Thermo Fisher Scientific, Inc.) and blocked with 5% skimmed milk at room temperature for 2 h. The membranes were then incubated with specific primary antibodies at 4°C overnight. The following primary antibodies were used: anti-E-cadherin (cat. no. 3195T; 1:1,000; Cell Signaling Technology, Inc.), anti-N-cadherin (cat. no. 13116T; 1:1,000; Cell Signaling Technology, Inc.), anti-Vimentin (cat. no. 5741T; 1:1,000; Cell Signaling Technology, Inc.), anti-Snail (cat. no. 3879T; 1:1,000; Cell Signaling Technology, Inc.), anti-XBP1s/u (cat. no. bs-1668R; 1:1,000; Bioss) and anti-GAPDH (cat. no. 5174T; 1:1,000; Cell Signaling Technology, Inc.). Following the primary antibody incubation, the membranes were incubated with an HRP-conjugated secondary antibody for 1.5 h at room temperature. Protein bands were visualized using an ECL reagent (MilliporeSigma) and the bands were semi-quantified using ImageJ software (version 1.52r; National Institutes of Health). The gray value of the target protein was normalized to that of GAPDH.

**Statistical analysis.** Data are presented as the mean ± SD and statistical analysis was performed using GraphPad Prism 8.0 software (GraphPad Software, Inc.). All experiments were repeated independently in triplicate. One way ANOVA followed by a Tukey's post hoc test was used to analyze the significant differences among multiple groups. P<0.05 was considered to indicate a statistically significant difference.

**Results**

**circ-BIRC6 expression levels are upregulated in BC cell lines and circ-BIRC6 knockdown inhibits the proliferation of BC cells.** Firstly, the expression levels of circ-BIRC6 in several BC cell lines (SW780, T24, J82 and 5637) and a human immortalized uroepithelium cell line (SV-HUC-1) were detected using RT-qPCR. As presented in Fig. 1A, circ-BIRC6 expression was found to be upregulated in BC cell lines compared with the SV-HUC-1 cells, especially in the T24 cells, which were used for the subsequent experiments. Next, circ-BIRC6 was silenced in T24 cells via transfection with sh-circ-BIRC6#1 or sh-circ-BIRC6#2. The results revealed that BIRC6 expression was significantly downregulated in the sh-circ-BIRC6 groups.
compared with the sh-NC group, and T24 cells transfected with sh-circ-BIRC6#1 decreased the expression of circ-BIRC6 to a greater extent than sh-circ-BIRC6#2 (Fig. 1B). Therefore, sh-circ-BIRC6#1 was selected for use in further experiments. The results demonstrated that cell proliferation was markedly reduced following circ-BIRC6 knockdown compared with the sh-NC group (Fig. 1C). Moreover, the colony formation assay results revealed that the proliferative ability of T24 cells was markedly suppressed in the sh-circ-BIRC6#1 group compared with the sh-NC group (Fig. 1D). Simultaneously, the expression levels of the proliferation-related protein, Ki-67, were significantly decreased following circ-BIRC6 knockdown compared with the sh-NC group (Fig. 1E). These findings suggested that circ-BIRC6 may be upregulated in BC cells and that circ-BIRC6 knockdown may decrease the proliferation of BC cells.

circ-BIRC6 knockdown prevents the invasion, migration and epithelial-mesenchymal transition (EMT) of BC cells. Subsequently, the effects of BIRC6 knockdown on cell invasion were measured using a Transwell assay. As shown in Fig. 2A and B, the invasive ability of T24 cells was significantly inhibited in the sh-circ-BIRC6#1 group compared with the sh-NC group. Consistently, the results from the wound healing assay showed the same trend with cell migration (Fig. 2C and D). In addition, the expression levels of EMT-related proteins were analyzed using western blotting. The expression levels of E-cadherin were significantly upregulated in the sh-circ-BIRC6#1 group compared with the sh-NC group, while the expression levels of N-cadherin, vimentin and snail family transcriptional repressor 1 (snail) were downregulated in T24 cells following circ-BIRC6 knockdown (Fig. 2E). These results indicated that circ-BIRC6 knockdown may block the invasion, migration and EMT of BC cells.

circ-BIRC6 acts as a sponge for miR-495-3p. To study the mechanism via which circ-BIRC6 promotes BC progression, the potential miRNAs binding to circ-BIRC6 were predicted using the StarBase database (http://starbase.sysu.edu.cn), which identified miR-495-3p as a candidate molecule. A putative binding site between circ-BIRC6 and miR-495-3p was identified and is presented in Fig. 3A. The expression levels of miR-495-3p were significantly downregulated in BC cells compared with SV-HUC-1 cells (Fig. 3B). After successful transfection of T24 cells with the miR-495-3p mimic (Fig. 3C), the relative luciferase activity of the circ-BIRC6 WT vector was reduced compared with the mimic NC group (Fig. 3C and D). Moreover, circ-BIRC6 knockdown significantly upregulated the expression levels of miR-495-3p in T24 cells compared.
with the sh-NC group (Fig. 3E), further suggesting that circ-BIRC6 may act as a sponge for miR-495-3p.

**miR-495-3p inhibitor rescues the effects induced by circ-BIRC6 knockdown in BC cells.** To further elucidate the regulatory association between circ-BIRC6 and miR-495-3p in BC, the mRNA expression levels of miR-495-3p were successfully silenced via transfection with a miR-495-3p inhibitor (Fig. 4A). Co-transfection with miR-495-3p inhibitor and sh-circ-BIRC6#1 enhanced the proliferative ability of T24 cells compared with those in cells transfected with sh-circ-BIRC6#1 alone, which was accompanied by an increase in Ki-67 expression (Fig. 4B-E).

**Figure 2.** circ-BIRC6 silencing suppresses the invasion, migration and EMT of bladder cancer cells. (A and B) Transwell assay was used to evaluate the effects of BIRC6 silencing on the invasion of T24 cells. Magnification, x100. (C and D) Cell migration was evaluated using a wound healing assay. (E) Expression levels of EMT-associated proteins, including E-cadherin, N-cadherin, vimentin and snail, were determined using western blotting. **P<0.01, ***P<0.001 vs. sh-NC. NC, negative control; sh, short hairpin RNA; circ-BIRC6, circular RNA baculoviral IAP repeat-containing 6; EMT, epithelial-mesenchymal transition; snail, snail family transcriptional repressor 1.

**circ-BIRC6 regulates the expression levels of XBP1 via modulating miR-495-3p.** The bioinformatics results identified that XBP1 was a potential target gene of miR-495-3p, which was confirmed using a dual luciferase reporter assay (Fig. 6A and B). Furthermore, compared with SV-HUC-1 cells, the mRNA and protein expression levels of XBP1s/u were upregulated in BC cell lines when compared with SV-HUC-1 cells (Fig. 6C and D). Notably, T24 cells transfected with sh-circ-BIRC6#1 exhibited a decreased expression level of XBP1s/u compared with the
ZHOU et al: ROLE OF circRNA BIRC6 IN THE PROGRESSION OF BLADDER CANCER

sh‑NC group, which was blocked by the miR‑495‑3p inhibitor (Fig. 6E and F). Taken together, these data provide evidence to indicate that circ‑BIRC6 may regulate the expression level of XBPI via modulating miR‑495‑3p.

circ‑BIRC6 silencing suppresses the growth of BC xenografts by regulating the miR‑495‑3p/XBPI signaling axis. Next, to analyze the role of circ‑BIRC6 in BC, a BALB/c nude mice model was established. The xenograft results demonstrated

Figure 3. circ‑BIRC6 acts as a sponge for miR‑495‑3p. (A) Binding region between circ‑BIRC6 and miR‑495‑3p is shown. (B) Expression levels of miR‑495‑3p in several BC cell lines were determined using RT‑qPCR. **P<0.01 vs. SV‑HUC‑1. (C) RT‑qPCR was employed to detect the expression levels of miR‑495‑3p in T24 cells. ***P<0.001 vs. mimic NC. (D) Relative luciferase activities were detected in T24 cells. ****P<0.001 vs. circ‑BIRC6 WT + mimic NC. (E) miR‑495‑3p expression was assessed using RT‑qPCR in T24 cells following circ‑BIRC6 silencing. ***P<0.001 vs. sh‑NC, NC, negative control; sh, short hairpin RNA; circ‑BIRC6, circular RNA baculoviral IAP repeat‑containing 6; miR, microRNA; RT‑qPCR, reverse transcription‑quantitative PCR; Luc, luciferase; R, Renilla; WT, wild‑type; MUT, mutant.

Figure 4. miR‑495‑3p inhibitor restores the effects of circ‑BIRC6 knockdown on the proliferation of bladder cancer cells. (A) miR‑495‑3p expression was evaluated using reverse transcription‑quantitative PCR after transfection with the miR‑495‑3p inhibitor. **P<0.01 vs. NC inhibitor. (B) Cell proliferation was assessed using a Cell Counting Kit‑8 assay. ***P<0.001 vs. sh‑NC; ##P<0.01 vs. sh‑circ‑BIRC6#1 + NC inhibitor. (C) Ki‑67 expression was assessed using immunofluorescence. Magnification, x200. (D) Fluorescence intensity from part (C).

NC, negative control; sh, short hairpin RNA; circ‑BIRC6, circular RNA baculoviral IAP repeat‑containing 6; miR, microRNA.
that circ-BIRC6 knockdown notably inhibited tumor weight and volume compared with the sh-NC group (Fig. 7A-D). By contrast, the miR-495-3p inhibitor partially counteracted the inhibitory effects of circ-BIRC6 knockdown on the growth of tumors. Additionally, notably downregulated XBP1s/u expression was observed in tumor tissues of xenograft mice in the sh-circ-BIRC6#1 group compared with the sh-NC group, while miR-495-3p knockdown markedly reversed their expression levels (Fig. 7E and F). Moreover, immunohistochemical detection of Ki-67 staining demonstrated that silencing of circ-BIRC6 inhibited Ki-67 expression in tumor tissues compared with the sh-NC group (Fig. 7G). It was also found that the tumor tissues that were transplanted with T24 cells (silenced for circ-BIRC6 and miR-495-3p expression) exhibited an elevated expression of Ki-67 when compared with sh-circ-BIRC6#1 + NC inhibitor group. Moreover, it was identified that circ-BIRC6 knockdown notably upregulated the expression levels of E-cadherin, but downregulated those of N-cadherin, vimentin and snail compared with the sh-NC group (Fig. 7H). The results also indicated that the miR-495-3p inhibitor partially abrogated the effect of circ-BIRC6 silencing on the expression levels of the aforementioned proteins. These data suggested that circ-BIRC6 knockdown may suppress the growth of BC cancer xenografts by regulating the miR-495-3p/XBP1 signaling axis.

Discussion

Previous studies have reported that circRNAs participate in the occurrence and progression of numerous cancer types, such as glioma, gastric and bladder cancer, by acting as sponges of miRNAs and keeping target genes away from miRNAs (19-21). There is an urgent requirement to increase the current understanding of the molecular mechanisms underlying BC development. In the present study, it was first demonstrated that circ-BIRC6 expression was upregulated in BC cell lines. Functional experiments identified that circ-BIRC6 silencing suppressed the progression of BC by mediating the behaviors of cancer cells (proliferation, invasion, migration and EMT). In addition, the results of the mechanistic studies revealed that circ-BIRC6 silencing suppressed the progression of BC by mediating the behaviors of cancer cells (proliferation, invasion, migration and EMT). In the present study, it was first demonstrated that circ-BIRC6 expression was upregulated in BC cell lines. Functional experiments identified that circ-BIRC6 silencing suppressed the progression of BC by mediating the behaviors of cancer cells (proliferation, invasion, migration and EMT).
The EMT process is accompanied by the downregulation of epithelial markers (E-cadherin) and upregulation of mesenchymal markers (N-cadherin, vimentin and snail) (28,29). In this regard, interruption of the aforementioned processes is an effective method to inhibit cancer development. In the present study, circ-BIRC6 knockdown upregulated E-cadherin expression and downregulated N-cadherin, Vimentin and Snail expression.

circRNAs have been found to participate in tumorigenesis by regulating multiple biological processes, such as growth, migration and invasion (30-32). circ-BIRC6 was reported to accelerate the progression of non-small cell lung cancer by potently promoting the proliferation, invasion and migration of cancer cells (33). In addition, it was revealed that circ-BIRC6 knockdown suppressed E-cadherin expression and downregulated N-cadherin, Vimentin and Snail expression.

circRNAs can function as ceRNAs to regulate biological activity by sponging miRNAs to completely or partially relieve their suppression of target mRNAs (34). With regards to their underlying mechanism, the current study bioinformatics analysis predicted that miR-495-3p was a potential target miRNA of circ-BIRC6, which was verified using a dual luciferase reporter assay. According to previous studies, miR-495-3p exerted a tumor suppressive effect in several cancer types. For instance, miR-495-3p expression was found to be downregulated in colorectal cancer (35). Moreover, miR-495-3p restrained the proliferation, invasion and migration of osteosarcoma cells by directly targeting complement C1q/TNF-related protein 3 (36). It is also worth noting that miR-495-3p expression was reported to be downregulated in glioma tissues and cells, and that miR-495-3p overexpression markedly inhibited the proliferation, invasion and EMT of glioma cells (37). In the present study, circ-BIRC6 was upregulated in BC cell lines, and silencing of circ-BIRC6 notably suppressed the proliferation, invasion, migration and EMT process of BC cells, suggesting the inhibitory effects of circ-BIRC6 on the progression of BC.

Figure 6. circ-BIRC6 regulates the expression of XBP1 via miR-495-3p. (A) Binding region between XBP1 and miR-495-3p is shown. (B) Relative luciferase activities were detected in T24 cells. **P<0.01 vs. XBP1 WT+ mimic NC. Protein and mRNA expression levels of XBP1 were examined using (C) western blotting and (D) RT-qPCR, respectively. ****P<0.0001 SV-HUC-1. (E) Western blotting and (F) RT-qPCR were employed to measure the protein and mRNA expression levels, respectively, of XBP1 after co-transfection with sh-circ-BIRC6#1 and miR-495-3p inhibitor. **P<0.01 vs. sh-NC; ***P<0.001 vs. sh-circ-BIRC6#1 + NC inhibitor. NC, negative control; sh, short hairpin RNA; circ-BIRC6, circular RNA baculoviral IAP repeat-containing 6; miR, microRNA; XBP1, X-box binding protein 1; WT, wild-type; MUT, mutant; Luc, luciferase; R, Renilla; RT-qPCR, reverse transcription-quantitative PCR.
miR-495-3p expression was markedly downregulated in BC cell lines. Notably, transfection with the miR-495-3p inhibitor partially restored the inhibitory effects on BC progression caused by circ-BIRC6 knockdown in BC cells.

Figure 7. circ-BIRC6 silencing suppresses the growth of bladder cancer xenografts via regulating the miR-495-3p/XBP1 signaling axis. (A and B) Photographs of tumors. (C) Tumor weights. (D) Growth curves of T24 tumor volume. mRNA and protein expression of XBP1 in tumor tissues of nude mice were examined using (E) reverse transcription-quantitative PCR and (F) western blotting, respectively. (G) Ki-67 expression was evaluated using immunohistochemical staining. Magnification, x200. (H) Expression levels of epithelial-mesenchymal transition-related proteins, including E-cadherin, N-cadherin, vimentin and snail, were examined using western blotting. ***P<0.001 vs. sh-NC; ##P<0.01, ###P<0.001 vs. sh-circ-BIRC6#1 + NC inhibitor. NC, negative control; sh, short hairpin RNA; circ-BIRC6, circular RNA baculoviral IAP repeat-containing 6; miR, microRNA; XBP1, X-box binding protein 1; snail, snail family transcriptional repressor 1.
Subsequently, the present study identified that XBP1 was a direct target of miR-495-3p. XBP1 is a key factor involved in endoplasmic reticulum stress. In general, XBP1 encodes two subtypes: XBP1s contains nuclear localization signals and transcriptional activation domains, while XBP1u contains nuclear rejection signals (38). XBP1s/u is an indicator of XBP1s activity, which, as an independent prognostic indicator, can be used to predict the overall survival of patients with myeloma (39). The loss of XBP1 was discovered to prevent glioma growth and promote cellular apoptosis (40). Furthermore, XBP1 was found to accelerate proliferation and invasion in human esophageal squamous cell carcinoma by upregulating the expression levels of MMP9 (41). Additionally, it was reported that XBP1 induced snail expression to promote the EMT and invasion of breast cancer cells (42). Emerging evidence supports the notion that elevated XBP1s/u is associated with a poor prognosis in patients with BC (43). In the current study, it was demonstrated that XBP1s/u expression was markedly upregulated in BC cell lines, and that XBP1 expression was regulated by the circ-BIRC6/miR-495-3p signaling axis. The xenograft results further verified the inhibitory effects of circ-BIRC6 knockdown on the growth and EMT of BC via interacting with miR-495-3p/XBP1.

In conclusion, to the best of our knowledge, the present study demonstrated for the first time that circ-BIRC6 was highly expressed in BC cells. Functionally, circ-BIRC6 knockdown inhibited the proliferation, invasion, migration and EMT of BC cells. Mechanistically, circ-BIRC6 knockdown suppressed BC progression in vitro and in vivo via a novel circ-BIRC6/miR-495-3p/XBP1 signaling regulatory network. These findings highlight a novel regulatory mechanism (circ-BIRC6/miR-495-3p/XBP1 signaling axis) in BC for researchers in this field to explore further, thereby identifying a new theoretical basis for targeted therapy. However, the lack of studies verifying the clinical value of circ-BIRC6 in clinical BC tissue samples and experiments showing any dose effect of circ-BIRC6 silencing (such as initial cell cycle arrest that would lead to inhibition of cell proliferation) as well as the usage of only one BC cell line to clarify the effects of the circ-BIRC6/miR-495-3p/XBP1 signaling axis in BC are potential limitations of the present research. Additionally, whether the overexpression of circ-BIRC6 would enhance the tumorigenesis of normal cells (SV-HUC-1) should also be further investigated. Therefore, comprehensive and in-depth analyses are required in the future to validate the findings of the current study.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

LZ, BW and YZ searched the literature and designed and performed the experiments. LZ, KY and BL analyzed and interpreted the data and wrote the manuscript. BW revised the manuscript. LZ and BL confirm the authenticity of all the raw data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol was approved by the Ethics Committee of The Third Xiangya Hospital, Central South University (Changsha, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin 67: 6-30, 2017.
2. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 71: 96-108, 2017.
3. Ploeg M, Aben KK and Kiemeneij LA: The present and future burden of urinary bladder cancer in the world. World J Urol 27: 289-293, 2009.
4. Roupret M, Babjuk M, Compérat E, Zigeuner R, Sylvester RJ, Burger M, Cowan NC, Gontero P, Van Rhijn BWG, Mostafid AH, et al: European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 Update. Eur Urol 73: 111-122, 2018.
5. Burger M, Grossman HB, Droller M, Schmidbauer J, Hermann G, Drăgoescu O, Ray E, Fradet Y, Karl A, Burgués JP, et al: Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data. Eur Urol 64: 846-854, 2013.
6. Chen M, Zhuang C, Liu Y, Li J, Dai F, Xia M, Zhan Y, Lin J, Chen Z, He A, et al: Tetracycline-inducible shRNA targeting antisense long non-coding RNA HIF1A-AS2 represses the malignant phenotypes of bladder cancer. Cancer Lett 376: 155-164, 2016.
7. Wilusz JE and Sharp PA: Molecular biology. A circuitous route to noncoding RNA. Science 340: 440-441, 2013.
8. Zhang W, Liu T, Li T and Zhao X: Hsa_circRNA_102002 facilitates metastasis of papillary thyroid cancer through regulating miR-488-3p/HAS2 axis. Cancer Gene Ther 28: 229-235, 2021.
9. Jia YJ, Liu M and Wang S: CircRNA hsa_circRNA_0001776 inhibits proliferation and promotes apoptosis in endometrial cancer via downregulating LRIG2 by sponging miR-182. Cancer Cell Int 20: 412, 2020.
10. Sun Z, Niu S, Xu F, Zhao W, Ma R and Chen M: CircAMOTL1 promotes tumorigenesis through miR-520b/SIK2 axis in cervical cancer. Front Cell Dev Biol 8: 568190, 2020.
11. Yan D, Dong W, He Q, Yang M, Huang L, Kong J, Qin H, Lin T and Huang J: Circular RNA circPICALM sponges miR-1265 to inhibit bladder cancer metastasis and influence FAK phosphorylation. EBioMedicine 48: 316-331, 2019.
12. Chen B, Wei W, Huang X, Xie X, Kong Y, Dai D, Yang L, Wang J, Tang H and Xie X: circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Theranostics 8: 4003-4015, 2018.
13. Yang G, Wang X, Liu B, Lu Z, Xu Z, Xiu P, Liu Z and Li J: circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis. Cell Cycle 18: 976-989, 2019.
XBP1s levels are implicated in the progression of breast cancer MDA-MB-231 cells. Phytother Res 33: 1934-1942, 2019.

Globin-exposed endothelial cells through miR-544a/FOXP1 and miR-379/FOXPA2 pathways. Mol Ther Nucleic Acids 10: 331-348, 2018.

CIRC_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY) 11: 10626-10643, 2019.

The BIRC6 gene as a novel target for therapy of prostate cancer. Dual targeting of inhibitors of apoptosis. Oncotarget 8: 161-170, 2013.

Circular RNA_LARP4 inhibits cell proliferation and invasion in human esophageal squamous cell carcinoma. Am J Cancer Res 6: 2031-2040, 2016.

Aging (Albany NY) 11: 10626-10643, 2019.

CIRC_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY) 11: 10626-10643, 2019.

CIRC_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY) 11: 10626-10643, 2019.

Circular RNA circ-ZKSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence. Mol Cancer 18: 133, 2019.

Circular RNA circRNA_103809 accelerates bladder cancer progression and enhances chemoresistance by activation of miR-516a-5p/ FBXL18 Axis. Cancer Manag Res 12: 7561-7568, 2020.

Circular RNA circRNA_100876 is upregulated in gastric cancer (GC) and promotes the GC cells' growth, migration and invasion via miR-665/YAP1 signaling. Front Genet 11: 546275, 2020.

The BIRC6 gene as a novel target for therapy of prostate cancer: Dual targeting of inhibitors of apoptosis. Oncotarget 8: 161-170, 2013.

Circular RNA circRNA_103809 accelerates bladder cancer progression and enhances chemoresistance by activation of miR-516a-5p/ FBXL18 Axis. Cancer Manag Res 12: 7561-7568, 2020.

Circular RNA circRNA_100876 is upregulated in gastric cancer (GC) and promotes the GC cells' growth, migration and invasion via miR-665/YAP1 signaling. Front Genet 11: 546275, 2020.

Yang H, Zhao M, Zhao L, Li P, Duan Y and Li G: Circular RNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145. Cell Oncol 43: 477-488, 2020.

Yang H, Zhao M, Zhao L, Li P, Duan Y and Li G: Circular RNA BIRC6 promotes non-small cell lung cancer cell progression by sponging microRNA-145. Cell Oncol 43: 477-488, 2020.

CIRC_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY) 11: 10626-10643, 2019.

Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer 16: 151, 2017.

Bi J, Liu H, Dong W, Xie W, He Q, Cai Z, Huang J and Lin T: Circular RNA circ-KSCAN1 inhibits bladder cancer progression through miR-1178-3p/p21 axis and acts as a prognostic factor of recurrence. Mol Cancer 18: 133, 2019.

Mi L, Liu Y, Liu J, Li W, Li N, Xue D, Zhang X and Wang P: Circ_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY) 11: 10626-10643, 2019.

CIRC_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY) 11: 10626-10643, 2019.

Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer 16: 151, 2017.

CIRC_0006332 promotes growth and progression of bladder cancer by modulating MYBL2 expression via miR-143. Aging (Albany NY) 11: 10626-10643, 2019.

Circular RNA_LARP4 inhibits cell proliferation and invasion of gastric cancer by sponging miR-424-5p and regulating LATS1 expression. Mol Cancer 16: 151, 2017.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.